NCEL · NewcelX Ltd. Ordinary Shares
View on chartInsiders & Stakes
| Michel Revel CSO and Director | ▲ Buy | Open Market | 957,530 Shares held | 4/27/2026 | View profile |
| Olivier Samuel Director | ▲ Buy | Open Market | 81,818 Shares held | 4/27/2026 | View profile |
Transaction History
| Olivier Samuel | ▲ Buy | Open Market | 81,818 | $225K | 4/27/2026 |
| Michel Revel | ▲ Buy | Open Market | 54,545 | $150K | 4/27/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
NewCelX Management to Attend Breakthrough T1D Congress
NewCelX management plans to attend the Breakthrough T1D Congress in Philadelphia to discuss its work on developing a cure for Type 1 Diabetes. This event highlights the company's ongoing research efforts in a critical area of medical science. The stock is currently trading near its 52-week low, reflecting the long-term nature of such development.
NewCelX Management to Attend Breakthrough T1D Congress. NewCelX management plans to attend the Breakthrough T1D Congress in Philadelphia to discuss its work on developing a cure for Type 1 Diabetes. This event highlights the company's ongoing research efforts in a critical area of medical science. The stock is currently trading near its 52-week low, reflecting the long-term nature of such development.